Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

Massimo Gentile; Marino Gentile; Fortunato Morabito; Francesco Morabito; Giovanni Del Poeta; Francesca Romana Mauro; Gianluigi Reda; Paolo Sportoletti; Luca Laurenti; Marta Coscia; Yair Herishanu; Anna Grazia Recchia; Marzia Varettoni; Roberta Murru; Annalisa Chiarenza; Adalgisa Condoluci; Riccardo Moia; Daniela Pietrasanta; Giacomo Loseto; Ugo Consoli; Ilaria Scortechini; Francesca Maria Rossi; Federica Maria Rossi; Antonella Zucchetto; Vincenzo Fraticelli; Ernesto Vigna; Cirino Botta; Giovanni Tripepi; Graziella D’ Arrigo; Angela Rago; Ilaria Angeletti; Annalisa Biagi; Ilaria Del Giudice; Riccardo Bomben; Gian Matteo Rigolin; Davide Rossi; Dario Rossi; Francesco Di Raimondo; Gianluca Gaidano; Aaron Polliack; Antonio Cuneo; Robin Foà; Robin Foa; Valter Gattei

doi:10.1038/s41375-020-0833-x

Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

Massimo Gentile
, Marino Gentile
, Fortunato Morabito
, Francesco Morabito
, Giovanni Del Poeta
, Francesca Romana Mauro
, Gianluigi Reda
, Paolo Sportoletti
, Luca Laurenti
, Marta Coscia
, Yair Herishanu
, Anna Grazia Recchia
, Marzia Varettoni
, Roberta Murru
, Annalisa Chiarenza
, Adalgisa Condoluci
, Riccardo Moia
, Daniela Pietrasanta
, Giacomo Loseto
, Ugo Consoli

Ilaria Scortechini, Francesca Maria Rossi, Federica Maria Rossi, Antonella Zucchetto, Vincenzo Fraticelli, Ernesto Vigna, Cirino Botta, Giovanni Tripepi, Graziella D’ Arrigo, Angela Rago, Ilaria Angeletti, Annalisa Biagi, Ilaria Del Giudice, Riccardo Bomben, Gian Matteo Rigolin, Davide Rossi, Dario Rossi, Francesco Di Raimondo, Gianluca Gaidano, Aaron Polliack, Antonio Cuneo, Robin Foà, Robin Foa, Valter Gattei

Hematology Unit AO of Cosenza
AO of Cosenza
University of Rome Tor Vergata
University “La Sapienza” of Rome
IRCCS Fondazione Ca'Granda – Ospedale Maggiore Policlinico - Milano
University of Perugia
Azienda Ospedaliera - Universitaria Città della Salute e della Scienza di Torino
Tel Aviv University
IRCCS Fondazione Policlinico San Matteo - Pavia
AO Brotzu
University of Catania
Oncology Institute of Southern Switzerland (IOSI)
University of Eastern Piedmont
Azienda Ospedaliera Nazionale Santi Antonio e Biagio e Cesare Arrigo
IRCCS Istituto tumori Giovanni Paolo II - Bari
Ospedale Garibaldi
Marche Polytechnic University
IRCCS Centro di Riferimento Oncologico - Aviano PN
National Research Council of Italy
ASL Roma 1
Azienda Ospedaliera S. Maria di Terni
University of Ferrara
Hadassah University Medical Centre

Research output: Contribution to journal › Article

Abstract

N/A

Original language	English
Pages (from-to)	235-238
Number of pages	4
Journal	Leukemia
Volume	35
DOIs	https://doi.org/10.1038/s41375-020-0833-x
Publication status	Published - 2021

Keywords

Adenine
Antineoplastic Agents, Immunological
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
Molecular Targeted Therapy
Piperidines
Prognosis
Protein Kinase Inhibitors
Treatment Outcome

Access to Document

10.1038/s41375-020-0833-x

Cite this

Gentile, M., Gentile, M., Morabito, F., Morabito, F., Del Poeta, G., Mauro, F. R., Reda, G., Sportoletti, P., Laurenti, L., Coscia, M., Herishanu, Y., Recchia, A. G., Varettoni, M., Murru, R., Chiarenza, A., Condoluci, A., Moia, R., Pietrasanta, D., Loseto, G., ... Gattei, V. (2021). Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. Leukemia, 35, 235-238. https://doi.org/10.1038/s41375-020-0833-x

@article{5dc5fd3b9a114e1ab56d1f9eba67c610,

title = "Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study",

abstract = "N/A",

keywords = "Adenine, Antineoplastic Agents, Immunological, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Molecular Targeted Therapy, Piperidines, Prognosis, Protein Kinase Inhibitors, Treatment Outcome, Adenine, Antineoplastic Agents, Immunological, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Molecular Targeted Therapy, Piperidines, Prognosis, Protein Kinase Inhibitors, Treatment Outcome",

author = "Massimo Gentile and Marino Gentile and Fortunato Morabito and Francesco Morabito and \{Del Poeta\}, Giovanni and Mauro, \{Francesca Romana\} and Gianluigi Reda and Paolo Sportoletti and Luca Laurenti and Marta Coscia and Yair Herishanu and Recchia, \{Anna Grazia\} and Marzia Varettoni and Roberta Murru and Annalisa Chiarenza and Adalgisa Condoluci and Riccardo Moia and Daniela Pietrasanta and Giacomo Loseto and Ugo Consoli and Ilaria Scortechini and Rossi, \{Francesca Maria\} and Rossi, \{Federica Maria\} and Antonella Zucchetto and Vincenzo Fraticelli and Ernesto Vigna and Cirino Botta and Giovanni Tripepi and Arrigo, \{Graziella D{\textquoteright}\} and Angela Rago and Ilaria Angeletti and Annalisa Biagi and \{Del Giudice\}, Ilaria and Riccardo Bomben and Rigolin, \{Gian Matteo\} and Davide Rossi and Dario Rossi and \{Di Raimondo\}, Francesco and Gianluca Gaidano and Aaron Polliack and Antonio Cuneo and Robin Fo{\`a} and Robin Foa and Valter Gattei",

year = "2021",

doi = "10.1038/s41375-020-0833-x",

language = "English",

volume = "35",

pages = "235--238",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

}

Gentile, M, Gentile, M, Morabito, F, Morabito, F, Del Poeta, G, Mauro, FR, Reda, G, Sportoletti, P, Laurenti, L, Coscia, M, Herishanu, Y, Recchia, AG, Varettoni, M, Murru, R, Chiarenza, A, Condoluci, A, Moia, R, Pietrasanta, D, Loseto, G, Consoli, U, Scortechini, I, Rossi, FM, Rossi, FM, Zucchetto, A, Fraticelli, V, Vigna, E, Botta, C, Tripepi, G, Arrigo, GD, Rago, A, Angeletti, I, Biagi, A, Del Giudice, I, Bomben, R, Rigolin, GM, Rossi, D, Rossi, D, Di Raimondo, F, Gaidano, G, Polliack, A, Cuneo, A, Foà, R, Foa, R & Gattei, V 2021, 'Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study', Leukemia, vol. 35, pp. 235-238. https://doi.org/10.1038/s41375-020-0833-x

TY - JOUR

T1 - Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

AU - Gentile, Massimo

AU - Gentile, Marino

AU - Morabito, Fortunato

AU - Morabito, Francesco

AU - Del Poeta, Giovanni

AU - Mauro, Francesca Romana

AU - Reda, Gianluigi

AU - Sportoletti, Paolo

AU - Laurenti, Luca

AU - Coscia, Marta

AU - Herishanu, Yair

AU - Recchia, Anna Grazia

AU - Varettoni, Marzia

AU - Murru, Roberta

AU - Chiarenza, Annalisa

AU - Condoluci, Adalgisa

AU - Moia, Riccardo

AU - Pietrasanta, Daniela

AU - Loseto, Giacomo

AU - Consoli, Ugo

AU - Scortechini, Ilaria

AU - Rossi, Francesca Maria

AU - Rossi, Federica Maria

AU - Zucchetto, Antonella

AU - Fraticelli, Vincenzo

AU - Vigna, Ernesto

AU - Botta, Cirino

AU - Tripepi, Giovanni

AU - Arrigo, Graziella D’

AU - Rago, Angela

AU - Angeletti, Ilaria

AU - Biagi, Annalisa

AU - Del Giudice, Ilaria

AU - Bomben, Riccardo

AU - Rigolin, Gian Matteo

AU - Rossi, Davide

AU - Rossi, Dario

AU - Di Raimondo, Francesco

AU - Gaidano, Gianluca

AU - Polliack, Aaron

AU - Cuneo, Antonio

AU - Foà, Robin

AU - Foa, Robin

AU - Gattei, Valter

PY - 2021

Y1 - 2021

N2 - N/A

AB - N/A

KW - Adenine

KW - Antineoplastic Agents, Immunological

KW - Humans

KW - Leukemia, Lymphocytic, Chronic, B-Cell

KW - Molecular Targeted Therapy

KW - Piperidines

KW - Prognosis

KW - Protein Kinase Inhibitors

KW - Treatment Outcome

KW - Adenine

KW - Antineoplastic Agents, Immunological

KW - Humans

KW - Leukemia, Lymphocytic, Chronic, B-Cell

KW - Molecular Targeted Therapy

KW - Piperidines

KW - Prognosis

KW - Protein Kinase Inhibitors

KW - Treatment Outcome

UR - http://hdl.handle.net/10807/184014

U2 - 10.1038/s41375-020-0833-x

DO - 10.1038/s41375-020-0833-x

M3 - Article

SN - 0887-6924

VL - 35

SP - 235

EP - 238

JO - Leukemia

JF - Leukemia

ER -

Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this